Our story

XEMPERIA SA, is a science-driven startup founded in 2023 by Prof. Curzio Rüegg, Dr. Sarah Cattin and Dr. Tuto Rossi,  as spin-off from the University of Fribourg, Switzerland. Built on over 25 years of pioneering translational cancer research and biomarker discovery expertise.

The Team

XEMPERIA, is driven by a passionate, multidisciplinary team with complementary expertise spanning cancer biology, oncology diagnostics, biostatistics, artificial intelligence, legal affairs, and business strategy. United by a shared mission to revolutionize breast cancer care, we harness cutting-edge science and innovation to transform early detection and monitoring.

Prof. Curzio Rüegg
CEO/CSO

MD, trained in internal medicine, immunology, cell and molecular biology (Basel, Zürich, San Francisco). Chair of Pathology, UNIFR, Friburg. 

PhD Sarah Cattin
CTO

PhD in Medical Sciences, UNIFR (Fribourg)Specialist in cancer biomarkers and molecular biology Extensive experience in  translational studies and cell analytics.

Dr. Tuto Rossi
CLO

Lawyer with extensive experience in creating and supporting start-ups. Law and notary firm, Bellinzona.

Dr. PD. Khalil Zaman
Head Medical Affairs

MD-PhD, PD, Clinical oncologist, Head Breast Center, Dept. of Oncology CHUV-UNIL, Lausanne, Switzerland.

Dr. Thibaud Spinetti
COO

PhD in Immuno-Oncology, with extensive experience in translational medicine, clinical studies, and regulatory affairs. PMP and GCP certified.

Dr. Ivana Domljanovic
Senior Scientist

PhD in Medical Sciences & Diagnostics and DNA nanotechnology. Research Associate, UNIFR, Fribourg.

The SAB

XEMPERIA is supported by a Scientific Advisors Board (SAB) consisting of leaders in cancer biology, cancer biomarkers, translational and clinical oncology

Prof. Klaus Pantel

Director of the Tumor Biology Institute, Universitäts Klinikum Eppendorf, Hamburg, Germany. Pioneer of the liquid biopsy field.

Prof. Suzette Delaloge

MD, Clinical oncologist, Director of the Interception medico-scientific program, Institut Gustave Roussy, (IGFR), Paris, France.

Prof. Christine Desmedt

PhD, Translational Breast Cancer, Research. Katholieke Universiteit Leuven (KLU), Leuven, Belgium.

Dr. Mauro Delorenzi

PhD, Biologist Translational Bioinformatics and Statistics. Emeritus head of Bioinformatics Core Facility (BCF) UNIL-SIB, Lausanne, Switzerland.

Prof. Olivia Pagani

MD, Clinical oncologist. Member of the International Breast Cancer Study Group (IBCSG). Emeritus head breast cancer clinic and research, IOSI, Bellinzona, Switzerland.

Prof. Christine Desmedt

PhD, Translational Breast Cancer, Research. Katholieke Universiteit Leuven (KLU), Leuven, Belgium

Interested in knowing more?